Specificity and Structure of a High Affinity Activin Receptor-like Kinase 1 (ALK1) Signaling Complex

被引:141
|
作者
Townson, Sharon A. [1 ]
Martinez-Hackert, Erik [1 ]
Greppi, Chloe [1 ]
Lowden, Patricia [1 ]
Sako, Dianne [1 ]
Liu, June [1 ]
Ucran, Jeffrey A. [1 ]
Liharska, Katia [1 ]
Underwood, Kathryn W. [1 ]
Seehra, Jasbir [1 ]
Kumar, Ravindra [1 ]
Grinberg, Asya V. [1 ]
机构
[1] Acceleron Pharma, Cambridge, MA 02139 USA
关键词
CRYSTAL-STRUCTURE; ACTIVATION; EXPRESSION; BMP9; ENDOTHELIUM; MECHANISM; DOMAIN; TOOL;
D O I
10.1074/jbc.M112.377960
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Activin receptor-like kinase 1 (ALK1), an endothelial cell-specific type I receptor of the TGF-beta superfamily, is an important regulator of normal blood vessel development as well as pathological tumor angiogenesis. As such, ALK1 is an important therapeutic target. Thus, several ALK1-directed agents are currently in clinical trials as anti-angiogenic cancer therapeutics. Given the biological and clinical importance of the ALK1 signaling pathway, we sought to elucidate the biophysical and structural basis underlying ALK1 signaling. The TGF-beta family ligands BMP9 and BMP10 as well as the three type II TGF-beta family receptors ActRIIA, ActRIIB, and BMPRII have been implicated in ALK1 signaling. Here, we provide a kinetic and thermodynamic analysis of BMP9 and BMP10 interactions with ALK1 and type II receptors. Our data show that BMP9 displays a significant discrimination in type II receptor binding, whereas BMP10 does not. We also report the crystal structure of a fully assembled ternary complex of BMP9 with the extracellular domains of ALK1 and ActRIIB. The structure reveals that the high specificity of ALK1 for BMP9/10 is determined by a novel orientation of ALK1 with respect to BMP9, which leads to a unique set of receptor-ligand interactions. In addition, the structure explains how BMP9 discriminates between low and high affinity type II receptors. Taken together, our findings provide structural and mechanistic insights into ALK1 signaling that could serve as a basis for novel anti-angiogenic therapies.
引用
收藏
页码:27313 / 27325
页数:13
相关论文
共 50 条
  • [41] Three novel mutations in the activin receptor-like kinase 1 (ALK-1) gene in hereditary hemorrhagic telangiectasia type 2 in Brazilian patients
    Assis, A. M.
    Costa, F. F.
    Arruda, V. R.
    Annichino-Bizzacchi, J. M.
    Bertuzzo, C. S.
    JOURNAL OF HUMAN GENETICS, 2007, 52 (03) : 237 - 243
  • [42] Three novel mutations in the activin receptor-like kinase 1 (ALK-1) gene in hereditary hemorrhagic telangiectasia type 2 in Brazilian patients
    A. M. Assis
    F. F. Costa
    V. R. Arruda
    J. M. Annichino-Bizzacchi
    C. S. Bertuzzo
    Journal of Human Genetics, 2007, 52 : 237 - 243
  • [43] Effects of Activin receptor-like kinase 7 (Alk7) activation by Activins in brown adipocytes
    Balkow, A.
    Jagow, J.
    Kilic, A.
    Pfeifer, A.
    NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 2015, 388 : S3 - S3
  • [44] Heterozygous disruption of activin receptor-like kinase 1 is associated with increased arterial pressure in mice
    Gonzalez-Nunez, Maria
    Riolobos, Adela S.
    Castellano, Orlando
    Fuentes-Calvo, Isabel
    de los Angeles Sevilla, Maria
    Oujo, Barbara
    Pericacho, Miguel
    Cruz-Gonzalez, Ignacio
    Perez-Barriocanal, Fernando
    ten Dijke, Peter
    Lopez-Novoa, Jose M.
    DISEASE MODELS & MECHANISMS, 2015, 8 (11) : 1427 - 1439
  • [45] Mutations in the activin receptor-like kinase 1 gene in hereditary haemorrhagic telangiectasia type 2
    Johnson, DW
    Berg, JN
    Baldwin, MA
    Gallione, CJ
    Marondel, I
    Yoon, SJ
    Stenzel, TT
    Speer, M
    PericakVance, MA
    Diamond, A
    Guttmacher, AE
    Jackson, CE
    Attisano, L
    Kucherlapati, R
    Porteous, MEM
    Marchuk, DA
    NATURE GENETICS, 1996, 13 (02) : 189 - 195
  • [46] Genetic and pharmacological targeting of activin receptor-like kinase 1 impairs tumor growth and angiogenesis
    Cunha, Sara I.
    Pardali, Evangelia
    Thorikay, Midory
    Anderberg, Charlotte
    Hawinkels, Lukas
    Goumans, Marie-Jose
    Seehra, Jasbir
    Heldin, Carl-Henrik
    ten Dijke, Peter
    Pietras, Kristian
    JOURNAL OF EXPERIMENTAL MEDICINE, 2010, 207 (01): : 85 - 100
  • [47] Reduced activin receptor-like kinase 1 activity promotes cardiac fibrosis in heart failure
    Morine, Kevin J.
    Qiao, Xiaoying
    Paruchuri, Vikram
    Aronovitz, Mark J.
    Mackey, Emily E.
    Buiten, Lyanne
    Levine, Jonathan
    Ughreja, Keshan
    Nepali, Prerna
    Blanton, Robert M.
    Oh, S. Paul
    Karas, Richard H.
    Kapur, Navin K.
    CARDIOVASCULAR PATHOLOGY, 2017, 31 : 26 - 33
  • [48] Three novel mutations in the activin receptor-like kinase 1 gene in hereditary hemorrhagic teleangiectasia
    Assis, A
    Ozelo, MC
    Annichino-Bizzacchi, JM
    Costa, FF
    Arruda, VR
    THROMBOSIS AND HAEMOSTASIS, 1999, : 341 - 341
  • [49] TGFβ SIGNALING VIA ALK1 REQUIRES ALK5 KINASE ACTIVITY IN CHONDROCYTES
    van Caam, A.
    Davidson, E. Blaney
    van der Kraan, P.
    OSTEOARTHRITIS AND CARTILAGE, 2017, 25 : S167 - S168
  • [50] Phase II evaluation of dalantercept, a soluble recombinant activin receptor-like kinase 1 (ALK1) receptor fusion protein, for the treatment of recurrent or persistent endometrial cancer: A An NRG Oncology/Gynecologic Oncology Group Study 0229N
    Makker, Vicky
    Filiaci, Virginia L.
    Chen, Lee-may
    Darus, Christopher J.
    Kendrick, James E.
    Sutton, Gregory
    Moxley, Katherine
    Aghajanian, Carol
    GYNECOLOGIC ONCOLOGY, 2015, 138 (01) : 24 - 29